Systemic inflammatory biomarkers for predicting clinical deterioration in traumatic brain injury


Creative Commons License

Erdaş S., Ateş S., Kocaşaban D. Ü., Tunçel C. U., OKUMUŞ M.

Neurology Asia, cilt.31, sa.1, ss.305-312, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.54029/2026fzc
  • Dergi Adı: Neurology Asia
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
  • Sayfa Sayıları: ss.305-312
  • Anahtar Kelimeler: Biomarkers, brain injuries, traumatic, emergency medicine, inflammation, C-reactive protein, prognosis
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Identifying patients at risk of early clinical deterioration is essential for timely intervention. Methods: We retrospectively analyzed adult patients with mild to moderate TBI admitted to a tertiary care center. Three biomarkers were calculated from admission labs: red cell distribution width-to-platelet ratio (RPR), C-reactive protein-to-albumin ratio (CAR), and neutrophil-to-lymphocyte ratio × RPR (NLTRP). The primary outcome was deterioration within 5 days, defined as a ≥2-point decline in Glasgow Coma Scale or need for mechanical ventilation. The secondary outcome was 28-day mortality. Results: Of 378 patients, 67 (17.7%) deteriorated and 30 (10.3%) died within 28 days. RPR (AUC 0.614, p=0.003) and CAR (AUC 0.609, p=0.005) predicted early deterioration. RPR (AUC 0.719, p<0.001), CAR (AUC 0.650, p=0.006), and NLTRP (AUC 0.645, p=0.008) predicted mortality. In multivariate analysis, CAR independently predicted early deterioration (OR 1.715, 95% CI 1.310-2.246). Conclusion: RPR, CAR, and NLTRP are inexpensive, routinely available markers that may assist in early risk stratification of mild to moderate TBI. Validation in prospective multicenter studies is warranted.